We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Roche’s immuno-oncology rivals are hurtling toward a showdown in previously untreated kidney cancer. But the Swiss drugmaker has decided to pull its horse out of the race.
University of North Carolina Lineberger Comprehensive Cancer Center scientists have uncovered a potential therapeutic target for kidney cancers that have a common genetic change.